Graphical Abstract Highlights d Topical application of peptide boosts antigen-specific T RM CD8 + T cells in the skin d Expanded T RM T cells enhance site-specific protective immunity d Expanded T RM T cells are derived from circulating memory CD8 + T cells d Recruited memory T cells become CD69 + T RM following local antigen encounter
In Brief
Tissue-resident memory (T RM ) T cells provide a first line of host defense against pathogen invasion at environmental barrier tissues. Here, Hobbs and Nolz describe a mechanism to rapidly expand the number of antigen-specific T RM CD8 + T cells in the skin, using topical application of antigenic peptide to boost localized protective immunity.
INTRODUCTION
Cellular immunity is largely mediated by CD4 + and CD8 + T cells and requires direct recognition of ''non-self'' peptides presented on major histocompatibility complexes (MHCs). Because many intracellular infections occur within non-lymphoid tissues, memory T cells must either be already positioned at the site of pathogen entry or be able to rapidly localize to inflamed tissues following re-infection. Traditionally, the goal of vaccination strategies targeting the formation of cellular immunity has been to generate large populations of circulating antigen (Ag)-specific memory T cells with booster immunizations and strong adjuvants (Gilbert, 2012; Slifka and Amanna, 2014) . In theory, expanding the number of memory T cells in the circulation would lead to increased surveillance of peripheral tissues and responsiveness to secondary challenge. However, in human vaccination trials targeting the prevention of AIDS, tuberculosis, and malaria, the numbers of circulating memory T cells have not correlated with protection, even after successful heterologous boosting (Buchbinder et al., 2008; McNatty et al., 2000; Tameris et al., 2013) . This lack of protection by circulating memory T cells has generated a strong interest in developing vaccines that seed tissue-resident memory (T RM ) T cells at sites of pathogen entry.
Although the factors governing the differentiation of T RM cells are not completely understood, recruitment of effector T cells into peripheral tissues can be sufficient to generate a T RM population (Casey et al., 2012; Mackay et al., 2012) . Thus, one approach to seed T RM cells within a target tissue is to prime a T cell response and recruit effector T cells into the tissue microenvironment by delivering recombinant chemokines or other non-specific inflammatory agents. Recent studies have reported that T RM cells generated using this ''prime and pull'' approach are highly protective against both infections and tumors (Gá lvez-Cancino et al., 2018; Mackay et al., 2012; Shin and Iwasaki, 2012) . However, the chemokines used in the recruitment phase only recruit effector (and not memory) CD8 + T cells; as a result, this technique only allows a short time frame in which seeding of T RM cells can occur and cannot be used to boost existing T RM populations (Shin and Iwasaki, 2012) . Further, the large population of effector and memory cells resulting from the transfer of monoclonal T cell receptor transgenic (TCR-tg) T cells may not accurately reflect the same trafficking and localization patterns of the relatively rare, polyclonal endogenous Ag-specific CD8 + T cell repertoire (Badovinac et al., 2007) . Here, we show that topical application of antigenic peptide to skin harboring endogenous T RM CD8 + T cells causes inflammation and locally expands the Ag-specific (but not bystander) T RM population by recruiting new T RM precursors from the circulation. This mechanism of T RM expansion significantly improved protective immunity in the skin, suggesting its potential utility as a tissue-and Ag-specific vaccine boosting strategy.
RESULTS

Viral Skin Infection Generates Protective Circulating and Tissue-Resident Memory T Cells
Skin infection with poxvirus vectors has become an attractive and widely used vaccine approach (Pastoret and Vanderplasschen, 2003) . Using a procedure similar to the smallpox immunization strategy (Hickman et al., 2013) , we infected the left ear skin of naive B6 mice with attenuated, thymidine kinase deficient (tkÀ) vaccinia virus (VACV) (Buller et al., 1985) and analyzed the accumulation of CD8 + T cells in the skin that were specific for the immunodominant epitope of VACV (H2-K b -B8R 20-27 ). B8R-specific CD8 + T cells trafficked into the infected skin between days 7 and 15 post-infection, and a stable population of 50-150 B8Rspecific memory CD8 + T cells formed in the previously infected skin $80 days after infection ( Figures 1A-1C ). B8R-specific CD8 + T cells that remained in the skin expressed the canonical T RM markers CD69 and CD103, whereas memory B8R-specific CD8 + T cells in the spleen did not ( Figures 1D-1F ). Together, these data demonstrate that VACV skin immunization generates Ag-specific memory CD8 + T cells in both the circulation and in the skin.
VACV infection generates robust humoral and cellular immunity that accelerates clearance of a secondary infection (Hammarlund et al., 2003) . To quantify the amount of protection provided by these arms of adaptive immunity, we treated mice that were immunized only on the left ear skin with control (immunoglobulin G; IgG) or anti-CD4/CD8 depleting antibodies (aCD4/8), which eliminated nearly all T cells from the spleen ( Figure 1G ) and CD69 À cells from the skin but did not deplete CD69 + T cells at the vaccination site ( Figures 1H and 1I ). Both the left and right ear skin were then infected with the more virulent parent strain of VACV (Western Reserve; VACV-WR). IgG-treated animals prevented VACV infection at the site of immunization as well as in distal unimmunized skin ( Figure 1J , IgG), demonstrating that the combination of circulating memory T cells and antibodies can be sufficient to rapidly control viral skin infection. However, when circulating memory T cells were eliminated, viral titers were reduced in immunized skin $50-fold compared to those in distal skin ( Figure 1J , aCD4/8).
These data demonstrate that VACV skin infection generates highly protective adaptive immunity, but endgogenous T RM cells provide site-specific protection even within the context of functional humoral immunity.
Activation of T RM CD8 + T Cells Causes Delayed Type
Hypersensitivity and Local Accumulation of Ag-Specific T RM CD8 + T Cells Topical application of antigenic peptide to T RM -containing skin causes delayed type hypersensitivity (DTH), characterized by tissue swelling and the recruitment of circulating lymphocytes (Ariotti et al., 2014; Gaide et al., 2015; Khan et al., 2016; Schenkel et al., 2013 Schenkel et al., , 2014 . Because only 50-150 B8R-specific T RM CD8 + T cells formed in the skin after VACV infection, we next tested whether this small population could also initiate a DTH response. We infected the left and right ear skin with tkÀ VACV and, at 35 days post-infection, topically applied a DMSO/acetone solution containing B8R 20-27 to the left ear skin and control peptide to the contralateral ear skin. B8R-challenged skin became inflamed ( Figure 2A ) and rapidly accumulated CD45 + leukocytes, CD8 + T cells, and B8R-specific CD8 + T cells ( Figures 2B-2D ). Peptide dissolved in a skin-penetrating DMSO/acetone solution was required, as leukocytes did not accumulate in skin challenged with B8R 20-27 suspended in an olive oil emulsion ( Figure S1A ). T RM CD8 + T cells were also necessary for this DTH reaction, because the skin of mice infected intravenously (i.v.) with VACV, which generated circulating B8R-specific memory CD8 + T cells but limited numbers of T RM CD8 + T cells in the skin (Figures S1B-S1D), did not become inflamed after B8R 20-27 challenge ( Figure 2A ). To determine the duration and durability of the DTH response, we allowed inflammation to subside ($10 days) and then re-challenged the skin with B8R 20-27 two additional times. The inflammatory response was a similar magnitude and duration following each challenge ( Figure 2E ), demonstrating that Ag-specific T RM CD8 + T cells remain highly functional after repeated activation.
We next determined whether repeated activation caused any changes to the B8R-specific T RM CD8 + T cell population in the challenged skin. Following resolution of the final episode of inflammation, the number of B8R-specific T RM CD8 + T cells increased significantly in B8R-stimulated skin compared to that in control skin ( Figures 2F and 2G ). B8R-specific T RM CD8 + T cells in skin challenged with control peptide remained mostly CD69 + /CD103 + , whereas the expanded B8R-specific T RM population became largely CD69 + /CD103 À (Figures 2F  and 2H ), which we have recently shown to be the dominant T RM CD8 + T cell population that forms following secondary VACV skin infection (Osborn et al., 2019) . Notably, T RM CD8 + T cells that were not B8R specific did not expand and remained CD69 + /CD103 + (Figures S2A-S2C ). B8R-specific CD8 + T cells in the spleen were not significantly boosted by peptide challenge (Figure 2I ), demonstrating that expansion was site specific and restricted to the Ag-specific T RM CD8 + T cell population (Figure 2J) . Critically, the increased number and CD69 + /CD103 À phenotype of B8R-specific CD8 + T cells were maintained 40 days after peptide challenge ( Figures S2D-S2F ), demonstrating the stability of the expanded B8R-specific T RM population.
Because B8R-specific T RM CD8 + T cells expanded exclusively in the skin following three rounds of B8R 20-27 peptide challenge, we next determined whether boosting T RM CD8 + T cells of a single Ag specificity would improve protection compared to the primary T RM population. We administered 3 rounds of B8R [20] [21] [22] [23] [24] [25] [26] [27] or control peptide to VACV-immunized skin (as in Figure 2E ), depleted circulating CD4 + and CD8 + T cells, and infected both distal and immunized skin with VACV-WR (as in Figure 1J ). In immunized skin, boosting the number of B8R-specific T RM CD8 + T cells increased protection by $50-fold compared to the primary T RM population ( Figure 2K ), whereas protection in distal skin was not affected. Together, these data demonstrate that activation of endogenous skin T RM CD8 + T cells causes acute DTH but also generates a larger population of secondary Ag-specific T RM CD8 + T cells that provide site-specific protective immunity.
Circulating Memory CD8 + T Cells Traffic into the Skin following Local T RM Activation and Accumulate in an Ag-Specific Manner To determine whether the rapid accumulation of CD8 + T cells following T RM activation was due to the recruitment of circulating memory CD8 + T cells, we treated mice with CD8 depleting antibody before peptide challenge, which eliminates CD8 + T cells from the circulation but spares T RM CD8 + T cells in the skin . When circulating CD8 + T cells were depleted, the number of CD8 + T cells and B8R-specific cells did not increase after peptide challenge ( Figures 3A-3C ), demonstrating that the increase of CD8 + T cells in the skin within 40 h of peptide challenge was due to the recruitment of memory CD8 + T cells from the circulation. Trafficking of memory CD8 + T cells into inflamed skin is dependent on their ability to bind P-/E-selectin on vascular endothelium (Nolz and Harty, 2014) . B8R-specific memory CD8 + T cells in the circulation expressed P-and E-selectin ligands ( Figures 3D and 3E ), and blocking P-and E-selectin prevented recruitment of CD45 + and CD8 + T cells (Figures S3A and S3B) and B8R-specific CD8 + T cells into the skin ( Figure 3F ).
To determine whether recruitment of circulating Ag-specific memory CD8 + T cells was required for the subsequent formation of an expanded, stable secondary T RM CD8 + T cell population, we depleted circulating CD8 + T cells and challenged the ear skin with 3 rounds of B8R [20] [21] [22] [23] [24] [25] [26] [27] . As shown previously ( Figures  2F-2H ), B8R-specific CD8 + T cells in the skin of IgG-treated mice expanded and formed a CD69 + /CD103 À secondary T RM population (Figures 3G-3I) . In contrast, mice that lacked circulating memory CD8 + T cells failed to accumulate B8R-specific T RM CD8 + T cells and remained mostly CD69 + /CD103 + ( Figures  3G-3I ). Together, these data demonstrate that the accumulation of CD69 + /CD103 -Ag-specific T RM CD8 + T cells requires the recruitment of memory CD8 + T cells from the circulation.
''Recruit and Capture'' Strategy to Establish Ag-Specific T RM CD8 + T Cells in the Skin It has been reported that recruitment of effector/memory CD8 + T cells into non-lymphoid tissues can be sufficient to generate T RM CD8 + T cells (Beura et al., 2018; Casey et al., 2012; Davies et al., 2017; Mackay et al., 2013; Shin and Iwasaki, 2012) . To test whether this occurs during a T RM -mediated DTH reaction, we transferred naive P14 CD8 + T cells and infected mice with lymphocytic choriomeningitis virus (LCMV), which generates robust circulating memory populations, but limited numbers of P14 CD8 + T cells can be isolated from the skin (Osborn et al., 2019) . LCMV-immune mice were then infected on the ear skin with VACV to generate B8R-specific T RM CD8 + T cells. Mice were then challenged with B8R 20-27 or control peptide, and Figure S1 ). On day 40 post-infection, B8R 20-27 or control peptide (NP 396-404 of LCMV) was applied to the left ear skin, and change in ear thickness was measured. (B-D) Mice were infected by scarification as in (A), and 40 h after peptide application, the numbers of CD45 + (B), CD8 + (C), and B8R-specific CD8 + (D) T cells in the skin were determined by flow cytometry. (E) Mice were infected on the left and right ear skin with VACV. On day 35 post-infection, skin was challenged with B8R 20-27 or control peptide, and swelling was monitored. Once swelling had subsided, mice were re-challenged two more consecutive times (arrows indicate peptide challenge). (F) Representative flow cytometry plots depicting B8R-specific CD8 + T cells and expression of CD69 and CD103 10 days after the final peptide challenge (see Figure S2 ). recruitment of P14 and B8R-specific CD8 + T cells was analyzed ( Figure 4A ). Both memory P14 and B8R-specific CD8 + T cells rapidly trafficked into the skin within 40 h of B8R 20-27 challenge ( Figures 4B and 4C, 40h) , demonstrating that the recruitment of circulating memory CD8 + T cells is antigen independent. How-ever, in skin that was challenged with B8R peptide, only B8Rspecific CD8 + T cells were retained 10 days after the final challenge ( Figures 4B and 4C, 10d) , demonstrating that there is, essentially, no bystander T RM differentiation of recruited memory CD8 + T cells. This finding suggested that the B8R 20-27 peptide (D) Mice were infected on the skin with VACV, and on day 35 after infection, B8R-specific CD8 + T cells in the blood were analyzed for expression of P-and E-selectin ligands. Naive CD8 + T cells (CD62L + /CD44 À ) were used as a negative control for selectin binding. (E) Quantification of (D). (F) Mice were infected on the skin with VACV and received control IgG or P-/E-selectin blocking antibodies before challenge with B8R 20-27 or control peptide on day 40 post-infection. The number of B8R-specific CD8 + T cells in the skin 40 h after challenge was determined by flow cytometry (see Figure S3 ). (G) Mice were treated as in (A), except they were challenged three times with B8R 20-27 (as in Figure 2E (legend continued on next page) was responsible for both initiating recruitment and the subsequent accumulation of B8R-specific memory CD8 + T cells in the skin. Thus, we next tested whether a new T RM population could be established by recruiting circulating memory CD8 + T cells with B8R 20-27 and then ''capturing'' memory CD8 + T cells of a different Ag specificity by including an additional antigenic peptide ( Figure 4D) . To test this, we infected LCMV-immune mice on the left and right ear skin with VACV and, 30 days later, challenged the left ear skin with B8R 20-27 /GP 33-41 and the right ear skin with B8R 20-27 /control peptide 3 times ( Figure 4E ). Thirty days after the final peptide challenge, B8Rspecific CD8 + T cells accumulated at both sites equally, but significantly more GP 33-41 -specific CD8 + T cells were retained in the B8R 20-27 /GP 33-41 -challenged skin compared to those in the B8R 20-27 /control-challenged skin (Figures 4F-4K ). B8R-specific CD8 + T cells were largely CD69 + /CD103 À at both sites, while the majority of GP 33-41 -specific CD8 + T cells were CD69 À /CD103 À in B8R 20-27 /control-challenged skin and mostly CD69 + /CD103 À in B8R 20-27 /GP 33-41 -challenged skin ( Figures  4F-4K) . Similar results were observed when TCR-tg P14 CD8 + T cells were used as the ''capture'' population ( Figure S4 ). Together, these data demonstrate that activation of established T RM CD8 + T cells is sufficient to recruit circulating memory CD8 + T cells, but the capture and subsequent differentiation into CD69 + T RM require Ag recognition within the skin.
DISCUSSION
Recently, we reported that the presence of local antigen enhances the formation of T RM CD8 + T cells during a primary VACV skin infection (Khan et al., 2016) , which agrees with our data presented here, demonstrating that antigen recognition by circulating memory CD8 + T cells within the skin microenvironment also controls the formation and retention of secondary T RM cells. This finding contrasts with a recent study demonstrating bystander T RM differentiation following herpes simplex virus 1 (HSV-1) skin infection (Park et al., 2018) , suggesting that the mechanisms controlling T RM differentiation may also be dictated by the nature of the inflammatory microenvironment. Most secondary T RM CD8 + T cells do not express CD103, which is consistent with our recent observation that skin-T RM CD8 + T cells that are derived from circulating memory cells are intrinsically unable to express CD103, but are, in fact, T RM cells (Osborn et al., 2019) . Interestingly, human skin contains approximately twice as many T cells as the entire vascular system, and these skin-resident T cells are nearly all CD69 + but heterogeneous in terms of CD103 expression (Clark, 2015) . In contrast, T RM populations generated in laboratory mice following a single infection are generally smaller than circulating T cell populations and nearly all CD69 + /CD103 + (Gebhardt et al., 2009; Mackay et al., 2013) . Our results suggest that recurring encounters with pathogens or environmental antigens may contribute to the increased size and varied composition of the CD8 + T cell populations observed in human skin.
In summary, we demonstrate that topical application of a single antigenic peptide boosted the number of antigen-specific T RM CD8 + T cells in the skin and was sufficient to increase local protective immunity against a homologous infection. The secondary T RM CD8 + T population was derived from circulating memory CD8 + T cells that were recruited into the skin and differentiated into a CD69 + /CD103 À T RM CD8 + T cell following local antigen encounter. Importantly, because this mechanism of expansion only relies on stable circulating memory T cell populations, boosting T RM populations within the skin could occur at any time after successful immunization. Additionally, because all circulating memory CD8 + T cells are recruited to the site of challenge, de novo T RM populations can be generated by including additional peptides that will capture recruited memory CD8 + T cells. Thus, our study demonstrates that topical application of antigenic peptides may offer a cheap and simple strategy to boost protective T RM CD8 + T cell populations at environmental barrier tissues such as the skin.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (E-K) Mice were infected with LCMV and, 30 days later, were infected with VACV. Mice were then challenged three times with a mixture of B8R plus control peptide (OVA 257-264 ) or B8R plus GP [33] [34] [35] [36] [37] [38] [39] [40] [41] 
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jeffrey Nolz (nolz@ohsu.edu) . This study did not generate new unique reagents. REAGENT 
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice C57BL/6N mice (6-10 weeks of age, female) were from Charles River/NCI. For adoptive transfers, 2.5 3 10 4 P14 CD8 + Thy1.1 + T cells (Pircher et al., 1989) were injected i.v. in 200 mL of PBS. All animal experiments were approved by the OHSU Institutional Animal Care and Use Committee.
METHOD DETAILS
Infections LCMV-Armstrong infections (2 3 10 5 pfu) were performed by i.p. injection in a volume of 200 ml. VACV-WR, tk-VACV, and VACV-GP 33-41 were maintained by propogation in BSC-40 cells as previously described (Wyatt et al., 2017) . VACV skin infections were performed on anesthetized mice by placing 10 7 pfu of virus (in 10 mL of PBS) on the ventral side of the ear pinna, and then poking the virus-coated skin 25 times with a 27-gauge needle. VACV titers from infected skin was determined using standard plaque assays as described previously (Khan et al., 2016) . Briefly, infected ears were removed and homogenized in 1 mL of RPMI containing 1% FBS. Homogenates were subjected to three rounds of freeze-thaw and serial dilutions were inoculated on BSC-40 cells in a 12 well plate that was then covered with 1% Seakem agarose. Plaques were visualized three days later after overnight incubation with neutral red dye. All infectious agents were approved by the OHSU Institutional Biosafety Committee.
Topical peptide challenge B8R 20-27 , GP 33-41 , NP 396-404 , and OVA 257-264 peptides were dissolved in 20-40 ml of 4:1 acetone/DMSO or olive oil/H 2 O. The DMSO/ acetone formulation was chosen to enhance the penetration of the peptides and to aid in covering the entire surface area of the ear skin.The peptide solution was applied to anesthetized mice on the dorsal and ventral side of previously infected ears using a pipette tip. Ear pinna thickness was measured with a dial micrometer (Ames).
Leukocyte isolation from skin Skin tissue was incubated for 1.5 h at 37 C with 1 mL HBSS (GIBCO) containing CaCl 2 and MgCl 2 supplemented with 125 U/ml collagenase II (Invitrogen) and 60 U/ml DNase-I (Sigma-Aldrich). Leukocytes were purified from whole-tissue suspensions by resuspending the cells in 10 mL of 35% Percoll (GE Healthcare)/HBSS followed by centrifugation at 500 g for 10 minutes at room temperature with no brake (Osborn et al., 2017) . Cell numbers in skin were quantified by flow cytometry without any bead standardization.
Antibodies
Depleting antibodies (100-200 mg) targeting CD4 (GK1.5) or CD8a (2.43) were delivered i.p. and CD8b (YTS156.77) and CD4 (RM4-5) fluorescent antibodies were used to confirm depletion five days after antibody administration. P/E-selectin (RB40/9A9) blocking antibodies (200 mg) were administered 18 hours before and at the time of peptide challenge.
Cell staining and flow cytometry
Staining for surface antigens was performed in PBS/1% fetal bovine serum for 15 minutes at 4 C. For tetramer binding, cells were incubated for 45 minutes at room temp. P/E-selectin binding was determined by incubating cells with P-or E-selectin human IgG Fc chimeric proteins (R&D Systems) for 30 minutes in 1% FBS/Dulbecco's PBS containing Ca 2+ and Mg 2+ (GIBCO) at room temperature. Selectin binding was detected using anti-human IgG Fc phycoerythrin (eBioscience). Cells were then stained with fluorescent antibodies as described above. Data was acquired using either a BD LSRII Flow Cytometer in the OHSU Flow Cytometry Core Facility. Flow cytometry data was analyzed using FlowJo software, version 9.9 or 10.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical tests and experimental details for each experiment are stated in the figure legend. Statistical tests were performed using Prism software (version 6.0; GraphPad Software). * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
DATA AND CODE AVAILABILITY
No new datasets or code were generated in this paper.
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